Heparin-induced thrombocytopenia: pathogenesis and management.
Warkentin
Theodore E
TE
Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton, Ontario, Canada. twarken@mcmaster.ca
D000917:Antibody Formation; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D000941:Antigens / Q000276:immunology; D006403:Hematologic Tests; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D015539:Platelet Activation; D013917:Thrombin / Q000378:metabolism; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology; D013927:Thrombosis / Q000139:chemically induced / Q000188:drug therapy*
D000925:Anticoagulants; D000941:Antigens; D007074:Immunoglobulin G; D006493:Heparin; D013917:Thrombin